New global Phase I/II ARROS-1 results reported a clinically meaningful activity signal for zidesamtinib in TKI-naive advanced or metastatic ROS1-positive NSCLC, with a 94% response rate cited for the study cohort. The update strengthens the evidence base for ROS1-targeted kinase strategies designed to compete with existing ROS1 options and expands the dataset for treatment-naive settings. The findings provide an additional momentum datapoint as sponsors increasingly emphasize response depth and durability when prioritizing escalation toward later development.